We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Read MoreHide Full Article
Key Takeaways
Teva's ecopipam NDA won FDA priority review, with a decision expected in late Q1 2027.
Ecopipam reduced tic severity and cut the risk of relapse by 53% over 12 weeks in pediatric responders.
Teva added ecopipam through its $700 million Emalex deal, strengthening its neuroscience pipeline.
Teva Pharmaceuticals (TEVA - Free Report) announced that the FDA has accepted the new drug application ("NDA") seeking approval for its investigational drug, ecopipam (EBS-101). Ecopipam is a first-in-class selective dopamine D1 receptor antagonist being developed for the treatment of pediatric patients with Tourette syndrome.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected in late first quarter of 2027. If approved, ecopipam could become the first new Tourette syndrome therapy in more than 10 years and the first novel mechanism of action in more than 50 years.
Year to date, TEVA's shares have gained 20% compared with the industry’s 8.6% growth.
Image Source: Zacks Investment Research
A priority review designation means the FDA’s goal is to take action on an application within six months compared with 10 months under standard review.
Ecopipam was added to Teva’s pipeline in June with the acquisition of Emalex Biosciences for $700 million in upfront cash. The acquisition strengthened Teva’s late-stage neuroscience pipeline and supports its Pivot to Growth strategy.
Tourette syndrome is a chronic neurodevelopmental disorder that causes involuntary motor and vocal tics, typically beginning in childhood. The condition affects approximately 100,000 children and adolescents in the United States, with symptoms often disrupting daily life. Many patients discontinue current treatments due to limited efficacy or treatment-related side effects, highlighting the need for better options.
Teva’s Strong D1AMOND Data Support Ecopipam NDA
The NDA filing for ecopipam in pediatric Tourette syndrome was backed by positive data from phase IIb and phase III D1AMOND studies. In the phase IIb study, ecopipam significantly reduced tic severity compared with placebo, achieving a statistically significant improvement in the Yale Global Tic Severity Scale-Total Tic Score at week 12, with efficacy maintained in the long-term open-label extension. The phase III randomized-withdrawal study further demonstrated durability, with pediatric responders receiving ecopipam showing a 53% lower risk of relapse over 12 weeks.
The drug was generally well-tolerated in clinical studies, with commonly reported side effects.
Teva’s Broader Neuroscience Pipeline
Beyond ecopipam, Teva is advancing several other neuroscience assets, including olanzapine long-acting injectable ("LAI") and emrusolmin (TEV-286). Olanzapine LAI is under regulatory review in the United States and European Union, with Teva targeting a U.S. launch in the fourth quarter of 2026, subject to approval. Emrusolmin is being evaluated in a phase II study for multiple system atrophy. The candidate is being developed in collaboration with MODAG.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX's shares have risen 43.7% year to date.
Amneal Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN's shares have increased 71.3% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU's shares have declined 17.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Key Takeaways
Teva Pharmaceuticals (TEVA - Free Report) announced that the FDA has accepted the new drug application ("NDA") seeking approval for its investigational drug, ecopipam (EBS-101). Ecopipam is a first-in-class selective dopamine D1 receptor antagonist being developed for the treatment of pediatric patients with Tourette syndrome.
With the FDA granting priority review to the NDA, a decision from the regulatory body is expected in late first quarter of 2027. If approved, ecopipam could become the first new Tourette syndrome therapy in more than 10 years and the first novel mechanism of action in more than 50 years.
Year to date, TEVA's shares have gained 20% compared with the industry’s 8.6% growth.
Image Source: Zacks Investment Research
A priority review designation means the FDA’s goal is to take action on an application within six months compared with 10 months under standard review.
Ecopipam was added to Teva’s pipeline in June with the acquisition of Emalex Biosciences for $700 million in upfront cash. The acquisition strengthened Teva’s late-stage neuroscience pipeline and supports its Pivot to Growth strategy.
Tourette syndrome is a chronic neurodevelopmental disorder that causes involuntary motor and vocal tics, typically beginning in childhood. The condition affects approximately 100,000 children and adolescents in the United States, with symptoms often disrupting daily life. Many patients discontinue current treatments due to limited efficacy or treatment-related side effects, highlighting the need for better options.
Teva’s Strong D1AMOND Data Support Ecopipam NDA
The NDA filing for ecopipam in pediatric Tourette syndrome was backed by positive data from phase IIb and phase III D1AMOND studies. In the phase IIb study, ecopipam significantly reduced tic severity compared with placebo, achieving a statistically significant improvement in the Yale Global Tic Severity Scale-Total Tic Score at week 12, with efficacy maintained in the long-term open-label extension. The phase III randomized-withdrawal study further demonstrated durability, with pediatric responders receiving ecopipam showing a 53% lower risk of relapse over 12 weeks.
The drug was generally well-tolerated in clinical studies, with commonly reported side effects.
Teva’s Broader Neuroscience Pipeline
Beyond ecopipam, Teva is advancing several other neuroscience assets, including olanzapine long-acting injectable ("LAI") and emrusolmin (TEV-286). Olanzapine LAI is under regulatory review in the United States and European Union, with Teva targeting a U.S. launch in the fourth quarter of 2026, subject to approval. Emrusolmin is being evaluated in a phase II study for multiple system atrophy. The candidate is being developed in collaboration with MODAG.
TEVA’s Zacks Rank & Stocks to Consider
Teva currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) and Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each, while AC Immune (ACIU - Free Report) carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX's shares have risen 43.7% year to date.
Amneal Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN's shares have increased 71.3% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU's shares have declined 17.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.